There is a current need for the development of new and effective vaccines for a variety of diseases. With the current scare from new and immerging infectious diseases such as H1N1, there is a strong push to develop more effective vaccines. Researchers at the University of Nebraska Medical Center have developed a novel vaccine adjuvant (EP67) that can successfully induce a cellular immune response against antigens derived from a variety of sources such as viral, bacterial, fungal, cancer, or even addictive substances. EP67 is a conformationally-biased and highly response-selective agonist of C5a that induces C5a-like immune stimulatory activities without activation of C5a-like inflammatory responses. EP67 can easily be conjugated to a variety of antigens such as peptides, whole proteins, or even virions and spores. When injected into the body, EP67 directs the antigen to an antigen presenting cell (APC), which leads to the activation of the APC and the initiation of a robust immune response without inducing inflammation. EP67 has been extensively tested in vitro and in vivo. Proof of concept data has been obtained for cancer and infectious disease based vaccines.